Literature DB >> 8521498

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

S A Kliewer1, J M Lenhard, T M Willson, I Patel, D C Morris, J M Lehmann.   

Abstract

Prostaglandins (PGs) of the J2 series form in vivo and exert effects on a variety of biological processes. While most of PGs mediate their effects through G protein-coupled receptors, the mechanism of action for the J2 series of PGs remains unclear. Here, we report the PGJ2 and its derivatives are efficacious activators of peroxisome proliferator-activated receptors alpha and gamma (PPAR alpha and PPAR gamma, respectively), orphan nuclear receptors implicated in lipid homeostasis and adipocyte differentiation. The PGJ2 metabolite 15-deoxy-delta 12,14-PGJ2 binds directly to PPAR gamma and promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes. These data provide strong evidence that a fatty acid metabolite can function as an adipogenic agent through direct interactions with PPAR gamma and furthermore, suggest a novel mechanism of action for PGs of the J2 series.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521498     DOI: 10.1016/0092-8674(95)90194-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  460 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes.

Authors:  S L Tilley; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Prostaglandin and PPAR control of immune cell function.

Authors:  Dino Rotondo; Jillian Davidson
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

4.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

Authors:  G Martin; H Duez; C Blanquart; V Berezowski; P Poulain; J C Fruchart; J Najib-Fruchart; C Glineur; B Staels
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

5.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

6.  The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export.

Authors:  Mark Hilliard; Cornelia Frohnert; Christiane Spillner; Simone Marcone; Annegret Nath; Tina Lampe; Desmond J Fitzgerald; Ralph H Kehlenbach
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

7.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.

Authors:  Y F Guan; Y H Zhang; R M Breyer; L Davis; M D Breyer
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

8.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

9.  Epidermis-type lipoxygenase 3 regulates adipocyte differentiation and peroxisome proliferator-activated receptor gamma activity.

Authors:  Philip Hallenborg; Claus Jørgensen; Rasmus K Petersen; Søren Feddersen; Pedro Araujo; Patrick Markt; Thierry Langer; Gerhard Furstenberger; Peter Krieg; Arjen Koppen; Eric Kalkhoven; Lise Madsen; Karsten Kristiansen
Journal:  Mol Cell Biol       Date:  2010-06-07       Impact factor: 4.272

10.  Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway.

Authors:  S Yamasaki; T Nakashima; A Kawakami; T Miyashita; H Ida; K Migita; K Nakata; K Eguchi
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.